Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Roche’s Home Healthcare Medical Device For Anticoagulant Therapy Launches In Europe

XTALKS VITALS NEWS

The Switzerland-based company’s medical device – CoaguChek INRange – monitors a patient’s response to Vitamin K Antagonist (VKA) therapy by measuring blood coagulation.

Share this!

June 2, 2016 | by Sarah Massey, M.Sc.

Roche has launched a new PT/INR home self-testing device for European patients taking anticoagulant drugs Tweet: Roche launches home #medicaldevice for patients taking anticoagulants http://ctt.ec/xovq6+. The home healthcare medical device market is a growing space, and new products have the potential to improve out-of-hospital care for patients.

The Switzerland-based company’s medical device – CoaguChek INRange – monitors a patient’s response to Vitamin K Antagonist (VKA) therapy by measuring blood coagulation. Since the medical device makes use of Bluetooth technology, it could help patients and physicians monitor treatment success more effectively compared to the current standard of care.

Currently, patients must visit a hospital or doctor’s office in order to assess how well they are responding to VKA therapy. The PT/INR testing is done using a blood test, for which lab results could take two to three days to be generated.

Roche’s CoaguChek INRange medical device uses a fingerstick – much like a glucose meter – with results in just 60 seconds. Along with reducing the number of visits to a physician’s office, the medical device could improve patient adherence to a monitoring schedule, thereby improving patient outcomes.



“In a clinical environment, we need to establish a model of care that empowers patients, helping them to understand their health condition and allowing them to take responsibility of their own health care needs,” said Dr. Juan Carlos Souto, of the Hospital de Sant Pau in Barcelona, Spain. “The new technology will enable us to access the test results in the clinic's database, to keep track of the individual patient's status and to measure the quality of care provided by our clinic.”

According to Roche, research has shown that patients using self-testing monitoring devices spend more time at normal INR levels, and may have a lower risk of bleeding and stroke. The company’s home testing medical device could also strengthen the doctor-patient relationship by facilitating communication.

“As healthcare systems face continued pressure to deliver improved access to care at a lower cost, increased connectivity between healthcare providers and patients becomes even more important,” said Roland Diggelmann, COO of Roche Diagnostics. “This is another proof point towards our aim to position patient self-testing as the standard of care to monitor VKA therapy.”


Keywords: Medical Device, Anticoagulant, Home Healthcare


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News


FDA Approves Puma Biotechnology’s Extended Adjuvant Therapy for Breast

July 19, 2017 - Puma Biotechnology’s breast cancer drug Nerlynx (neratinib) has been approved by the US Food and Drug Administration (FDA).

Featured In: Biotech News


CAR-T Cell Therapy Shows Promise as Leukemia Treatment in Early Stage Clinical Trial

July 19, 2017 - About 70 percent of clinical trial participants with chronic lymphocytic leukemia experienced tumor shrinkage after being treated with CAR-T immunotherapy, according to researchers at Fred Hutchinson Cancer Research Center.

Featured In: Clinical Trial News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know

REGISTER FOR THESE WEBINARS

Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.